Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Manganese


General


Pronunciation

(MAN ga nees)


Brand Names: U.S.

  • Mangimin [OTC]
  • MN-50 [OTC]

Indications


Use: Labeled Indications

Trace element added to total parenteral nutrition (TPN) solution to prevent manganese deficiency; orally as a dietary supplement


Contraindications


Direct IM or IV injection


Dosing and Administration


Dosing: Adult

Adequate intake: Oral:

Males: 2.3 mg/day; Females: 1.8 mg/day

Pregnancy: 2 mg/day

Lactation: 2.6 mg/day

Deficiency prevention: IV: 150-800 mcg/day usually administered in TPN solutions


Dosing: Geriatric

Refer to adult dosing.


Dosing: Pediatric

Adequate intake: Oral:

0-6 months: 0.003 mg/day

7-12 months: 0.6 mg/day

1-3 years: 1.2 mg/day

4-8 years: 1.5 mg/day

9-13 years: Males: 1.9 mg/day; Females: 1.6 mg/day

14-18 years: Males: 2.2 mg/day; Females: 1.6 mg/day

Deficiency prevention: IV: 2-10 mcg/kg/day usually administered in TPN solutions

Note: Use caution in premature neonates; manganese chloride solution for injection contains aluminum.


Dosing: Renal Impairment

Use caution; manganese chloride solution for injection contains aluminum.


Dosing: Hepatic Impairment

Use caution; dose may need to be decreased or withheld.


Administration

Capsule, tablet: May be administered with a meal.

Solution for injection: Do not administer IM or by direct IV injection; acidic pH of the solution may cause tissue irritations and it is hypotonic; administer after dilution in volume of fluid ≥100 mL


Storage

Capsule/tablet (dietary supplement): Store in a cool, dry place.

Solution for injection: Store at controlled room temperature of 20 ‚ °C to 25 ‚ °C (68 ‚ °F to 77 ‚ °F). Compatible with electrolytes usually present in amino acid/dextrose solution used for TPN solutions; after admixture, discard unused portion immediately.


Dosage Forms/Strengths


Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral, as chelated:

MN-50: Elemental manganese 16.67 mg

Solution, Intravenous, as chloride:

Generic: Elemental manganese 0.1 mg/mL (10 mL)

Solution, Intravenous, as sulfate [preservative free]:

Generic: Elemental manganese 0.1 mg/mL (10 mL)

Tablet, Oral, as aspartate:

Generic: 93 mg [elemental manganese 25 mg]

Tablet, Oral, as chelated:

Mangimin: Elemental manganese 10 mg [corn free, rye free, wheat free]

Generic: Elemental manganese 15 mg, Elemental manganese 50 mg

Tablet, Oral, as gluconate:

Generic: 50 mg [elemental manganese 5.7 mg]


Drug Interactions

There are no known significant interactions.


Monitoring Parameters

Periodic manganese plasma level


Warnings/Precautions


Disease-related concerns:

- Biliary tract impairment: Use with caution in patients with biliary tract impairment; dose may need to be decreased or withheld.

- Hepatic impairment: Use with caution in patients with hepatic impairment; dose may need to be decreased or withheld.

Dosage form specific issues:

- Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer 's labeling.

Other warnings/precautions:

- Appropriate use: Due to its highly acidic pH (pH 2.0), direct IV or IM injection is contraindicated; may result in severe tissue damage.


Pregnancy Risk Factor

C


Pregnancy Considerations

Animal reproduction studies have not been conducted. Manganese crosses the placenta and can be detected in placental tissue and cord blood (Osada, 2002).


Actions


Pharmacology

Cofactor in many enzyme systems, stimulates synthesis of cholesterol and fatty acids in liver, and influences mucopolysaccharide synthesis


Absorption

Poor


Distribution

Concentrated in mitochondria of pituitary gland, pancreas, liver, kidney, and bone


Excretion

Bile (primarily); urine (negligible)


Patient and Family Education


Patient Education

- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating, and advising patients.

Copyright © 2016 - 2017
Doctor123.org | Disclaimer